Odyssey Therapeutics (NASDAQ:ODTX) Announces Quarterly Earnings Results

Odyssey Therapeutics (NASDAQ:ODTX) issued its quarterly earnings data on Wednesday. The company reported $999.00 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.31) by $1,000.31, reports.

Odyssey Therapeutics Trading Up 3.2%

NASDAQ ODTX opened at $19.07 on Friday. Odyssey Therapeutics has a 52 week low of $15.35 and a 52 week high of $20.30.

Insider Buying and Selling at Odyssey Therapeutics

In other news, Director Dimension Capital Ii, L.P. purchased 1,111,111 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $19,999,998.00. Following the completion of the acquisition, the director directly owned 3,333,516 shares in the company, valued at approximately $60,003,288. The trade was a 50.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Tpg Gp A, Llc acquired 1,388,889 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $18.00 per share, with a total value of $25,000,002.00. Following the completion of the transaction, the insider owned 3,690,146 shares of the company’s stock, valued at approximately $66,422,628. This trade represents a 60.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 4,183,777 shares of company stock valued at $75,319,986 over the last ninety days.

Analyst Ratings Changes

ODTX has been the subject of a number of research reports. Zacks Research upgraded Odyssey Therapeutics to a “hold” rating in a research note on Wednesday, June 3rd. Oppenheimer reiterated an “outperform” rating and set a $40.00 price target on shares of Odyssey Therapeutics in a research report on Thursday. Wedbush started coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 price target on the stock. Cantor Fitzgerald assumed coverage on shares of Odyssey Therapeutics in a report on Tuesday, June 2nd. They set an “overweight” rating on the stock. Finally, JPMorgan Chase & Co. initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued an “overweight” rating and a $26.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Odyssey Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.